Eli Lilly plans to establish a new drug delivery and device innovation center in Cambridge, Mass.—a strategic location it says will help attract top scientists and bioengineers, as well as enhance Eli Lilly's local business development presence.
The Lilly Cambridge Innovation Center, located in Kendall Square, will allow life science experts and organizations to explore how emerging technologies and connectivity can advance drug delivery and device innovation to improve patient health.
John C. Lechleiter, Ph.D., Eli Lilly chairman, president and CEO, said the company is locating a portion of its delivery and device organization in Cambridge—one of the nation's leading regions for R&D of medical delivery technologies—to take advantage of the area's engineering talent base and life sciences ecosystem.
"The Lilly Cambridge Innovation Center complements a deliberate push by the company to be an industry leader in providing convenient, reliable drug delivery and device innovation," Lechleiter said. "Locating in Cambridge is an important strategic move for achieving this goal, as it provides us access to a concentration of high-caliber academic institutions, cutting-edge life science and technology companies and some of the world's leading talent."
Lechleiter added that the center will serve as a portal for external partnerships and collaboration activities with the company's existing research facilities in San Diego, New York City and Indianapolis.
Construction of the Lilly Cambridge Innovation Center will begin immediately, with an expected occupancy by the end of 2015. Over the next two years, the company will hire about 30 scientists and engineers to fulfill the center's work. When fully operational, the center will increase the company's delivery and device R&D space by nearly 50%, while increasing its staff by 25%.
The investment in Cambridge—part of the company's planned growth strategy in R&D of drug delivery and device technologies—"underscores Lilly's commitment to providing meaningful innovation in this arena," said Jan Lundberg, Ph.D., executive vice president of science and technology and president of Lilly Research Laboratories.
Lundberg said, "New drug delivery and device innovation is critically important to Lilly's growing portfolio of potential medicines, particularly in our focus areas of diabetes, neurodegeneration, immunology and pain. The best therapies of the future will marry breakthrough scientific discovery with customer-friendly devices. That's what will make life better for people who need our medicines and give Lilly a true competitive edge."
Eli Lilly's drug portfolio and pipeline have changed significantly over the past decade. More than half of the company's pipeline now comprises biologics that require some type of injection. The company expects its revenues from device-enabled products to double by 2020.